StreetAlpha.app
Home › Stocks › OABI

OmniAb, Inc. (OABI)

Healthcare
$4.66
▼ −7.36%
LAST CLOSE · NOV 20

OmniAb licenses an antibody discovery platform to drug developers and academic institutions. It last closed at $4.66 on Nov 20, down 7.36% on the day. The next earnings report for OABI is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, OABI reported EPS of -$0.12 on revenue of $4.0M, with revenue up 78.3% from a year ago. Over its last 8 reports the stock moved an average of 12.3% the session after earnings. Over the last 12 months OABI insiders bought $0 of stock on the open market and sold $283K, according to SEC Form 4 filings.

AI Auto Pilots
Is OABI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OABI.

Key Stats

Last 12 months
Results
Revenue
$40.2M
+90.6% vs a year ago
Net income
−$43.5M
−108.1% margin
EPS (diluted)
−$0.34
Free cash flow
$2.4M
5.9% margin
Valuation
Market cap
$679.7M
145.9M shares
P/E
–
No P/E while losing money
Price to sales
16.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.9M
At Sep 30
Shareholder equity
$249.2M
Shares outstanding
145.9M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $34.7M$34.7MFY2021FY2022: $59.1M$59.1MFY2022FY2023: $34.2M$34.2MFY2023FY2024: $26.4M$26.4MFY2024FY2025: $18.7M$18.7MFY2025

From OABI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · After the close
Reported EPS
-$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.14
Same quarter last year
Revenue
$4.0M
+78.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.13Dec '24Mar 2025: -$0.17Mar '25Jun 2025: -$0.15Jun '25Sep 2025: -$0.14Sep '25Dec 2025: -$0.11Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.12Sep '26Latest -$0.12
Revenue by quarter
Dec 2024: $10.8MDec '24Mar 2025: $4.2MMar '25Jun 2025: $3.9MJun '25Sep 2025: $2.2MSep '25Dec 2025: $8.4MDec '25Mar 2026: $14.4MMar '26Jun 2026: $13.4MJun '26Sep 2026: $4.0MSep '26Latest $4.0M
How OABI moved after its last 8 reports
Average move the session after a report ±12.3%
Oct 30, 2026Time not announced−2.3%
Aug 6, 2026After the close+37.5%
May 7, 2026After the close+12.9%
Mar 4, 2026After the close+10.5%
Nov 4, 2025After the close−3.7%
Aug 6, 2025After the close−2.6%
May 8, 2025After the close−8.3%
Mar 18, 2025After the close−20.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OABIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OABI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OABI

Technical Analysis

OABI · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 8% below its 20 day and 4% below its 50 day average. It is 37% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the swing low (Sep 28) at $4.55, and the nearest resistance the Pivot at $4.77.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.1%/day
Key levels
$5.4552 week high+17.0%
$5.0320 day average+7.9%
$4.94Pivot R1+6.0%
$4.93Swing high (Aug 26)+5.8%
$4.8250 day average+3.4%
$4.77Pivot+2.4%
$4.66Last close
$4.55Swing low (Sep 28)−2.4%
$4.50Pivot S1−3.4%
$3.97100 day average−14.8%
$2.94200 day average−36.9%
$1.3552 week low−71.0%
Indicators
RSI (14)42.76Middle of its rangeNeutral
MACD0.04Below its signal lineBearish
Stochastic38.0Middle of its rangeNeutral
ADX (14)14.0No clear trend
Williams %R-94.0Oversold below −80, overbought above −20Oversold
CCI (20)-111.7Oversold below −100, overbought above 100Oversold
Rate of change−7.4%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for OABI

What happened before

See how OABI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OABI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OABI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OABIHow many large options trades hit OABI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

OABI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲91 buying vs 59 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +31
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162131+23.7%
In funds' top 1032+50.0%
Held by funds48.0%40.4%+7.5 pts
New / increased43 / 4820 / 57+18.2%
Reduced / sold out46 / 1333 / 16+20.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OABI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OABI Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$283K12 sales · 3 insiders
2025-12 sold $89K2026-02 sold $144K2026-04 sold $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 7Charles S BerkmanChief Legal OfficerSale7,157$1.49$11K
Apr 7Kurt A GustafsonExecutive VP, Finance and CFOSale6,913$1.49$10K
Apr 7Matthew W FoehrPresident and CEOSale19,244$1.49$29K
Feb 18Matthew W FoehrPresident and CEOSale30,843$1.71$53K
Feb 18Charles S BerkmanChief Legal OfficerSale9,673$1.71$17K
Feb 18Kurt A GustafsonExecutive VP, Finance and CFOSale9,301$1.71$16K
Every insider buy and sale for OABI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OABI insider trades →

From SEC Form 4 filings by OABI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OABI is in one of them and how their past OABI trades turned out.

OABI in the AI portfolios
Loading…

OABI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OABI in an article yet. Here's the latest on the wider market.

OABI in the news

About OmniAb

OmniAb is a discovery research company based in Emeryville, California. It licenses its antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses genetically engineered rats, mice and chickens whose immune systems produce fully human antibody candidates, which are then screened to find those suited to a partner's drug development. Customers use the resulting antibodies in their own therapy programs.

Headquarters
Emeryville, CA